Portail Guide

Références

  1. Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis : A Review.JAMA 2020 ; 323: 1945-60.
  2. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; IMPACT project team. Global epidemiology of psoriasis: a systematic review of incidenceand prevalence. J Invest Dermatol 2013 ; 133: 377-8.
  3. Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med 2017 ; 17 : 65-70.
  4. Karmacharya P, Chakradhar R, Ogdie A. The epidemiology of psoriatic arthritis: A literature review. Best Pract Res Clin Rheumatol 2021 ; 35 : 101692.
  5. Menter A. Psoriasis and psoriatic arthritis overview. Am J Manag Care 2016 ; 22 (8 Suppl) : s216-24.
  6. Gervais E. Améliorer le diagnostic et la prise en charge du rhumatisme psoriasique, des questionnaires de dépistage à la consultation bi-disciplinaire. Rev Rhum Monographie 2020 ; 87: 302-6.
  7. Mulder MLM, van Hal TW, Wenink MH, et al. Clinical, laboratory, and genetic markers for the development of presence of psoriatic arthritis in psoriasis patients: a systematic review. Arthritis Res Ther 2021 ; 23: 168.
  8. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic Arthritis. N Engl J Med 2017; 376: 957-70.
  9. McGonagle DG, McInnes IB, Kirkham BW, Sherlock J, Moots R. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann Rheum Dis 2019 ; 78: 1167-78.
  10. Bridgewood C, Sharif K, Sherlock J, Watad A, McGonagle D. Interleukin-23 pathway at the enthesis: The emerging story of enthesitis in spondyloar- thropathy. Immunol Rev 2020 ; 294: 27-47.
  11. Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells. Nat Med 2012 ; 18: 1069-76.
  12. Jacques P, Lambrecht S, Verheugen E, et al. Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells. Ann Rheum Dis 2014 ; 73: 437-45.
  13. McGonagle D, Tan AL, Benjamin M. The nail as a musculoskeletal appendage-implications for an improved understanding of the link between psoriasis and arthritis. Dermatology 2009 ; 218: 97-102.
  14. Zabotti A, Tinazzi I, Aydin SZ, McGonagle D. From Psoriasis to Psoriatic Arthritis: Insights from Imaging on the Transition to Psoriatic Arthritis and Implications for Arthritis Prevention. Curr Rheumatol Rep 2020 ; 22 : 24.
  15. Eder L, Haddad A, Rosen CF, et al. The Incidence and Risk Factors for Psoriatic Arthritis in Patients With Psoriasis: A Prospective Cohort Study. Arthritis Rheumatol 2016 ; 68: 915-23.
  16. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008 ; 58 : 851-64.
  17. Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES),Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life QualityIndex (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res 2011; 63 (Suppl 11): S64-85.
  18. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis DiseaseActivity Index. J Rheumatol 1994; 21: 2286-91.
  19. Lukas C, LandewéR, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009 ; 68: 18-24.
  20. Helliwell PS, FitzGerald O, Fransen J, et al. The development of candidate composite diseaseactivity and responder indices for psoriatic arthritis (GRACEproject). Ann Rheum Dis 2013 ; 72: 986-91.
  21. Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 2011; 70: 272-7.
  22. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis : a proposed objective target for treatment. Ann Rheum Dis 2010 ; 69: 48-53.
  23. Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA) : defining remission and treatment success using the DAPSA score. Ann Rheum Dis 2016 ; 75: 811-8.
  24. Gossec L, de Wit M, Kiltz U, et al. A patient-derived and patient-reported outcome measure for assessing psoriaticarthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis 2014 ; 73: 1012-9.
  25. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 2020 ; 79: 700-12.
  26. Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol 2016 ; 68: 1060-71.
  27. Wendling D, Lukas C, Prati C, et al. 2018 update of French Society for Rheumatology (SFR) recommendations about the everyday management of patientswith spondyloarthritis. Joint Bone Spine 2018 ; 85 : 275-84.
  28. Mease PJ. Biologic Therapy for Psoriatic Arthritis. Rheum Dis Clin North Am 2015; 41: 723-38.
  29. Le Quellec A, Carvajal Alegria G, Guellec D, Saraux A. Place des inhibiteurs de JAK dans le traitement de la polyarthrite rhumatoïde. Rev Rhum Monographie 2018 ; 85: 19-24.
  30. Argobi Y, Smith GP. Analysis of the first 5 years of an interdisciplinary Rheumatology-Dermatology clinic.Clin Exp Dermatol2021 ; 46: 270-5.
  31. Theodorakopoulou E, Dalamaga M, Katsimbri P, Boumpas DT, Papadavid E. How does the joint dermatology-rheumatology clinic benefit both patients and dermatologists? Dermatol Ther 2020 ; 33: e13283.
© John Libbey Eurotext, 2022

Avec le soutien institutionnel des laboratoires